myeloid cells. Thus, lack of LEF-1 expression causes defective granulopoiesis in congenital neutropenia 34 , and elevated levels of constitutively active LEF-1 lead to hyperproliferation of myeloid progenitors and development of acute myeloid leukemia (AML) 34, 41 . LEF-1 activates granulopoiesis independently of β-catenin 34 . Myeloidspecific interaction partners of LEF-1 and the mechanisms by which LEF-1 expression is deregulated in patients with congenital neutropenia are unknown. Analysis of the pathological events downstream of HAX1 mutations may help to answer these questions.
RESULTS

HCLS1 protein interacts with LEF-1 protein
To identify hematopoietic-specific interaction partners of LEF-1, we carried out in silico analysis of LEF-1 protein using ScanSite software 42, 43 to identify motifs within the protein that are likely to bind other proteins. LEF-1 protein has a highly conserved HCLS1-binding site in the context-dependent domain at Pro191 (Fig. 1a) . HCLS1 was most highly expressed in myeloid cells compared with other lineages, as shown in a micrograph of a bone marrow section where myeloid cells and segmented granulocytes showed abundant HCLS1 staining (Fig. 1b) .
To confirm the binding of HCLS1 to LEF-1, we carried out immunoprecipitation experiments in HEK293T cells transfected with HCLS1 cDNA together with LEF-1 cDNA or mutant LEF-1 protein (LEF-1 Ala16), in which residues 186-192 were replaced by an alanineglycine sequence to eliminate the putative HCLS1-binding site. HCLS1 co-precipitated with wild-type (WT) LEF-1, but not with the LEF-1 Ala16 mutant (Fig. 1c) . We also detected an interaction between endogenous LEF-1 and HCLS1 proteins in lysates from the Jurkat cell line, which highly expresses HCLS1 and LEF-1 (Fig. 1d) .
We confirmed the interaction between native LEF-1 and HCLS1 proteins by blue native gel electrophoresis (BN-PAGE; first dimension) followed by identification of the proteins within the single protein complexes using SDS-PAGE (second dimension) and western blotting. We detected HCLS1, LEF-1, dominant-negative LEF-1 (dnLEF-1, which lacks the β-catenin-binding domain) and HAX1 in a single complex (Fig. 1e) . HAX1 was also found in a complex with LEF-1 in LEF-1-transfected HEK293T cells (Supplementary Fig. 1a) . In a pull-down assay using lysates from Jurkat cells, LEF-1 protein was pulled down by GST-HCLS1 protein but not by GST (Fig. 1f) . These data strongly support the existence of a direct interaction between HCLS1 and LEF-1.
HCLS1 is associated with Syk, Lyn and LEF-1 in CD34 + cells HCLS1 is known to be activated by phosphorylation upon treatment with hematopoietic cytokines such as erythropoietin 6 . Therefore, we analyzed whether stimulation of hematopoietic cells with G-CSF leads to HCLS1 phosphorylation. Indeed, in vitro G-CSF stimulation of human CD34 + cells showed time-dependent phosphorylation of HCLS1 protein on Tyr397 ( Supplementary Fig. 2a and Fig. 1g ), leading to enhanced interaction with LEF-1 ( Fig. 1h and data not shown). Mutation of the Tyr397 residue in the HCLS1 protein led to reduced binding of HCLS1 to LEF-1 (data not shown).
Although the association between HCLS1 with Lyn in nonstimulated CD34 + cells was weak, it was apparent after 30 min of G-CSF The interaction between native LEF-1 and HCLS1 was analyzed by isolating complexes on BN-PAGE (first dimension) followed by identification of proteins within the complexes by SDS-PAGE (second dimension) and western blotting for HCLS1, LEF-1, dnLEF-1 and HAX1. Shown are representative images of BN-PAGE with marker and Jurkat cell lysates as a positive control (left) and of western blot of complexes isolated from slices 3-7 of BN-PAGE (right). (f) Following pull-down assays of Jurkat cell lysates using human recombinant HCLS1-GST-tagged protein or GST protein, representative western blots are shown using antibodies to LEF-1 and HCLS1. (g) CD34 + bone marrow cells from two healthy individuals were treated with 10 ng ml −1 G-CSF. At the indicated time points, total and phospho-HCLS1 proteins were quantified using FACS analysis. Shown is the percentage of phospho-HCLS1 + cells in the HCLS1 + cell population. Data are mean ± s.d. and are derived from three independent experiments, each in duplicate, *P < 0.05. (h) Endogenous HCLS1 from primary bone marrow CD34 + cells treated or untreated with 10 ng ml −1 G-CSF for the indicated lengths of time was immunoprecipitated with antibody to HCLS1. Coimmunoprecipitates of LEF-1 and HCLS1 were detected by western blotting. Shown are representative western blot images of immunoprecipitates (top) and of the inputs used for immunoprecipitation (bottom); the isotype control for IP was negative (not shown). Lysate of untreated CD34 + cells was used as a positive control. Fig. 2b ). Moreover, although Syk constitutively interacted with HCLS1, the amount of HCLS1 bound to Syk was higher at 30 min of G-CSF stimulation as compared to control cells (Supplementary Fig. 2b ).
stimulation (Supplementary
We recently reported that G-SCF induces granulopoiesis via upregulation of the Nampt-NAD + -SIRT1 pathway 22 . Consistent with the results of that report, treatment of healthy individuals with the Nampt substrate nicotinamide led to a substantial upregulation of HCLS1 mRNA expression in bone marrow CD34 + and CD33 + cells, and treatment of CD34+ cells from healthy individuals with Nampt or G-CSF also led to a substantial upregulation of HCLS1 mRNA expression ( Supplementary Fig. 3a,b) .
HCLS1 is essential for G-CSF-triggered myelopoiesis
We previously identified HAX1 mutations in a group of patients with congenital neutropenia leading to an absence of HAX1 protein 29 . Notably, in CD33 + granulocytic progenitors from patients with congenital neutropenia harboring HAX1 mutations, G-CSF treatment did not upregulate HCLS1 mRNA expression, as compared to cells from healthy volunteers and patients with idiopathic or metabolic neutropenia ( Fig. 2a and Supplementary Fig. 4b ). In contrast, HAX1 mRNA levels were similar between the studied groups ( Supplementary Fig. 4a,b) . Similar to our previous observations 34 , and in line with lower expression of HCLS1 mRNA in congential neutropenia, LEF-1 mRNA and protein expression were much lower in CD33 + cells from such patients as compared with the other groups (Supplementary Fig. 4c ). Amounts of total and phospho-HCLS1 proteins were also lower in G-CSF-treated CD33 + myeloid progenitors from patients with congenital neutropenia (Fig. 2b and  Supplementary Fig. 5a ). In CD34 + cells from healthy individuals, HAX1 knockdown blocked HCLS1 phosphorylation following G-CSF treatment (Supplementary Fig. 5b-d) .
CD34 + cells transduced with HCLS1-or HAX1-specific shRNA and treated with G-CSF showed lower mRNA levels of LEF-1 target genes (encoding C/EBPα and ELA2, which are myeloid specific, as well as encoding cyclin D1 and survivin) but unchanged mRNA levels of other TCF family proteins and other proteins in the Nampt-SIRT pathway (TCF-3 and TCF-4, Nampt, SIRT1 and C/EBPβ), as compared with mock or control shRNA-transduced cells (Fig. 2c,d Table 1) .
We further analyzed the involvement of HCLS1 and HAX1 in G-CSF-induced granulocytic differentiation of CD34 + bone marrow cells of healthy individuals by a colony-forming unit (CFU) assay. After knockdown of HCLS1 or HAX1, in vitro granulocytic differentiation of CD34 + cells was significantly reduced (Fig. 2e and Supplementary Fig. 8a,b) , but the number of erythroid colonies (BFU-E) was only slightly reduced ( Supplementary Fig. 8c ). Knockdown of HCLS1 or HAX1 also inhibited ATRA-triggered differentiation of the NB4 promyelocytic cell line ( Supplementary Fig. 9a-c) . These results indicate that HCLS1 and HAX1 are essential for granulocytic differentiation in vitro.
HCLS1 affects LEF-1 nuclear translocation and activation
To evaluate the mechanisms of LEF-1 activation by HCLS1 in primary CD34 + cells, we first analyzed whether HCLS1 is involved in intracellular transport of the LEF-1 protein. We transduced CD34 + cells with a lentiviral construct expressing WT LEF-1 cDNA or LEF-1 cDNA with a mutated HCLS1-binding site (LEF-1 Ala16). After treatment of the cells with G-CSF for 15 min, WT LEF-1 but not LEF-1 Ala16 was predominantly localized in the nucleus (Fig. 3a) , suggesting a key role of HCLS1 in the nuclear transport of LEF-1.
In the next set of experiments, we knocked down endogenous HCLS1 in CD34 + cells; transduced the cells with cDNA encoding WT HCLS1, HCLS1 with a mutated nuclear localization signal (HCLS1 NLS) or HCLS1 with mutated Tyr397 (HCLS1 Y397F); treated the cells with G-CSF for 15 min; and evaluated the intracellular localization of LEF-1 and of LEF-1-HCLS1 and LEF-1-phospho-HCLS1 complexes using the Duolink in situ proximity ligation assay (PLA) [44] [45] [46] . In cells expressing WT HCLS1, G-CSF induced nuclear translocation of LEF-1. However, in the presence of HCLS1 Y397F or HCLS1 NLS, LEF-1 did not translocate to the nucleus (Fig. 3b) . Moreover, we (Fig. 3c,d) . We also found an interaction between endogenous LEF-1 and HAX1 proteins in CD34 + cells (data not shown). Similar effects were observed for endogenous HAX1 and phospho-HCLS1 proteins (data not shown). Furthermore, knockdown of HAX1 in CD34 + cells prevented the LEF-1-phospho-HCLS1 interaction (data not shown). Autoregulation of LEF-1 mRNA expression upon binding of LEF-1 protein to its own promoter is well established and is a common feature of many transcription factors. To evaluate the effects of HCLS1 on LEF-1 autoregulation, we generated a reporter gene construct comprising 3.6 kb of the human LEF1 gene promoter with five LEF-1-binding sites. G-CSF activated the LEF1 promoter in CD34 + cells; transfection of LEF-1 or HCLS1 cDNAs led to further upregulation of G-CSF-dependent LEF1 promoter activity, with synergistic effects of LEF-1 and HCLS1 (Fig. 3e) . However, a LEF-1 cDNA with a mutated HCLS1-binding site (encoding LEF-1 Ala16) did not activate the LEF-1 promoter. HCLS1 Y397F also did not activate the promoter, indicating that phosphorylation of HCLS1 is important for LEF-1 autoregulation. The HCLS1 NLS mutant also did not activate LEF1 gene promoter. The effects of LEF-1 and HCLS1 on G-CSF-triggered LEF1 promoter activation in CD34 + cells were severely diminished by knockdown of HCLS1 or HAX1 ( Supplementary Fig. 10a-c) . We observed similar effects on the CEBPA gene promoter in CD34 + cells ( Supplementary Fig. 11a-d) . We also observed similar effects in HEK293T cells on the LEF1 gene promoter and in these cells using the TOP-FOP flash plasmid system, in which the TOP reporter contains six LEF-1-and TCF-binding sites (which are lacking in the FOP reporter) ( Supplementary Fig. 12a -c and data not shown).
Consistent with these results, HCLS1 Y397F and HCLS1 NLS mutants did not activate mRNA expression of LEF-1 and LEF-1 target genes in CD34 + cells upon G-CSF treatment ( Fig. 3f and data not shown). The inhibitory effects of a LEF-1-specific shRNA on C/EBPα mRNA expression in CD34 + cells were rescued by LEF-1 or dnLEF-1 cDNAs , but not by the LEF-1 Ala16 mutant cDNA ( Supplementary  Fig. 12d ). In agreement with these findings, cells transduced with LEF-1 Ala16, HCLS1 Y397F or HCLS1 NLS showed reduced granulocyte colony and granulocyte-macrophage colony (CFU-G and CFU-GM) activities compared to control cells or cells transduced with WT LEF-1 or WT HCLS1 (Fig. 3g) .
We further analyzed whether HCLS1 activates LEF-1 target genes by binding to LEF-1 on chromatin. We carried out chromatin immunoprecipitation (ChIP) using chromatin from Jurkat cells. Using antibody to LEF-1, we first detected LEF-1 binding to chromatin of LEF-1 npg target genes (LEF1, CCND1 and CEBPA; first ChIP). In a second round, we carried out a re-ChIP experiment using DNA from the first round of ChIP, using antibody to LEF-1 (as positive control) or antibody to HCLS1 (second ChIP). We found that LEF-1 but not HCLS1 binds the LEF-1 target genes tested (Fig. 3h) .
Reciprocal feedback regulation of HCLS1 by LEF1 Because HCLS1 mRNA expression is activated by G-CSF in hematopoietic cells of healthy individuals, we analyzed whether LEF-1 could be involved in feedback regulation of HCLS1. In CD34 + cells, LEF-1 knockdown resulted in diminished HCLS1 mRNA and protein expression ( Supplementary Fig. 13a,b) . We identified two LEF-1-and three C/EBPα-binding sites within the 1,600-bp HCLS1 gene promoter and verified LEF-1 binding to the promoter by ChIP assay in CD34 + cells (Supplementary Fig. 13c,d) . We also made a reporter gene construct containing 1,600 bp of the HCLS1 gene promoter and found activation of the HCLS1 gene promoter by LEF-1 in HEK293T cells (Supplementary Fig. 13e ). HCLS1 promoter activity was induced by LEF-1 in CD34 + cells, and G-CSF treatment further enhanced LEF-1-triggered activation of promoter activity (Supplementary Fig. 13f ). LEF-1 knockdown or mutation of LEF-1-binding sites within the HCLS1 gene promoter substantially inhibited G-CSF-dependent activation of the promoter (Supplementary Fig. 13f ).
HCLS1 and HAX1 are involved in PI3K-Akt activation by G-CSF HCLS1 is associated with the PI3K-Akt pathway 9 , and this pathway is known to be activated by G-CSF 20 . We therefore wanted to determine whether HCLS1 is involved in G-CSF-triggered activation of PI3K-Akt signaling. Microarray analysis revealed substantial inhibition of the PI3K-Akt pathway by HCLS1-specific shRNA compared with control shRNA in CD34 + cells (Supplementary Table 3 ). Treatment of CD34 + cells with G-CSF led to phosphorylation of PI3K p85 (on Tyr458) and of Akt (on Ser473), which were both markedly reduced in cells transduced with HCLS1-or HAX1-specific shRNA (Fig. 4a,b) . Similarly, we detected much lower amounts of G-CSFdependent phospho-PI3K p85 (Tyr458) and phospho-Akt (Ser473) in CD34 + cells of patients with congenital neutropenia as compared with cells from healthy individuals (Supplementary Fig. 14a,b) . In experiments in which WT HCLS1 or HCLS1 NLS were expressed in CD34 + cells, removal of the NLS in HCLS1 did not affect G-CSF-triggered activation of PI3K or Akt (Fig. 4c,d ).
HCLS1 and HAX1 control G-CSF-induced F-actin rearrangement HCLS1 is involved in F-actin rearrangement 3, 9, 11, 12 , which is impaired in myeloid cells of patients with congenital neutropenia 47 . Microarray analysis showed marked defects in the actin regulatory pathway after HCLS1 knockdown (Supplementary Table 3 ).
We therefore determined whether G-CSF-triggered F-actin rearrangement depends on HCLS1 and/or HAX1. As in patients with congenital neutropenia 47 , basal F-actin amounts were significantly greater in CD34 + cells transduced with HAX1-or HCLS-specific shRNA compared with control shRNA ( Fig. 4e and Supplementary  Fig. 15a ). G-CSF treatment of CD34 + cells led to a rapid, transient increase in F-actin content, which was abrogated by HAX1 or HCLS1 knockdown ( Fig. 4f and Supplementary Fig. 15b ). However, expression of WT HCLS1 or HCLS1 NLS did not affect G-CSF-triggered F-actin rearrangement (Fig. 4g) .
To further test the role of HAX1 in F-actin dynamics, we used HEK293T cells, which do not express HCLS1 but express its homolog cortactin, and which also express HAX1. In HEK293T cells transfected with G-CSFR cDNA (293T-G-CSFR cells), we observed a fine, homogenous F-actin structure on the cell membrane and in the cytoplasm. This structure was rapidly redistributed after G-CSF treatment (Fig. 4h) , and this redistribution was blocked by HAX1 knockdown (Fig. 4i) .
Hcls1 −/− mice have mild neutropenia
We further evaluated the role of HCLS1 in granulopoiesis in vivo using Hcls1 −/− mice. We found significantly fewer peripheral blood neutrophilic granulocytes in Hcls1 −/− mice compared with WT mice (Fig. 5a ). In addition, Hcls1 −/− mice had moderately more monocytes and eosinophils, slightly fewer thrombocytes and similar numbers of lymphocytes and erythrocytes compared with WT mice (Supplementary Table 2 ). Consistent with these results, Hcls1 −/− mice had fewer Gr1 + Mac1 + cells (Fig. 5b) , slightly fewer granulocyte-monocyte progenitors and similar numbers of common myeloid progenitors and megakaryocyte-erythroid progenitors compared with WT littermates (Supplementary Fig. 16 ). mRNA and protein expression of LEF-1 and mRNA expression of LEF-1 target genes were significantly lower in Hcls1 −/− CD33 + bone marrow myeloid progenitors compared with cells of WT mice (Fig. 5c,d) . mRNA levels of Nampt, SIRT1 and C/EBPβ, which are involved in emergency granulopoiesis 22 , were similar or slightly higher in the Hcls1 −/− cells than in WT cells (Fig. 5c) . Bone marrow cells from Hcls1 −/− mice formed fewer CFU-G and CFU-M colonies, but similar numbers of BFU-E and CFU-Mega colonies, compared to cells from WT mice (Fig. 5e and Supplementary Fig. 17a ). Hcls1 −/− CFU-G colonies had lower expression of LEF-1 and C/EBPα mRNA, but higher expression of NAMPT, C/EBPβ and SIRT1 mRNA, compared with WT colonies (Supplementary Fig. 17b ). We next carried out a rescue experiment in which we transduced Hcls1 −/− bone marrow cells with HCLS1 cDNA constructs and assessed in vitro granulocytic differentiation using a liquid culture assay. Hcls1 −/− cells transduced with WT HCLS1 cDNA, but not with the HCLS1 Y397F or HCLS1 NLS cDNAs, showed elevated numbers of Gr-1 hi CD11b hi mature granulocytes, comparable to cells from WT mice (Fig. 5f) . Consistent with these observations, Hcls1 −/− cells transduced with WT HCLS1 cDNA had elevated amounts of LEF-1 and C/EBPα mRNA (Fig. 5g) .
Elevated levels of HCLS1 in human AML leukemic blasts
The functional outcomes of HCLS1 and LEF-1 action are dose dependent. For example, HCLS1 is hyperactivated in chronic lymphocytic leukemia 13 , and constitutively activated LEF-1 induces AML in mice 41 . Therefore, we were interested in determining the level of HCLS1 expression in AML blasts. Compared with CD34 + or CD33 + cells of healthy individuals, blast cells of patients with AML showed significantly higher expression of HCLS1 mRNA (Supplementary Fig. 18a ). Moreover, immunohistochemistry of tissue arrays containing bone marrow biopsies from patients with AML showed significantly higher HCLS1 protein expression in blasts of 46 of 52 (88.46%) patients with AML, as compared with biopsies from healthy individuals ( Fig. 6a and Supplementary Table 3) . Using Duolink PLA, we found that HCLS1 protein interacted with LEF-1 protein in primary AML blasts (data not shown). HCLS1 or LEF-1 knockdown in blasts of three patients with AML led to significantly lower cell proliferation and greater apoptosis, in agreement with lower mRNA expression of LEF-1 target genes (Fig. 6b, Supplementary  Fig. 18b and data not shown). Because HCLS1 is activated by G-CSF, we measured G-CSF expression in AML blasts and found substantial synthesis of G-CSF by these cells in three out of five patients, as compared with CD34 + hematopoietic or CD33 + myeloid progenitor cells of healthy individuals (Fig. 6c) . As not all of the patients with AML that we tested have G-CSF-producing leukemic cells, we carried out a meta-analysis of publicly available microarray data and found substantial mRNA upregulation of hematopoietic cytokines (G-CSF, TPO, SCF and EPO) and/or their receptors in AML blasts (Supplementary Table 4) . Therefore, autocrine production of G-CSF or other cytokines by AML blasts might underlie elevated HCLS1 expression.
Activating insertion in exon 12 of HCLS1 in patients with AML
To evaluate whether genetic abnormalities are responsible for elevated HCLS1 levels in patients with AML, we sequenced exons of the HCLS1 gene in such patients. We found a 12-bp insertion (1153insCCCGAGCCTGAG, NM_005335; Pro-Glu-Pro-Glu 366-367ins) in exon 12 of the HCLS1 gene, which encodes the prolinerich domain, in 89 of 135 patients with AML (65.9%) and in 41 of 104 healthy individuals (39.4%) ( Fig. 6d; Supplementary Table 5 ). 
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The percentage of patients with AML with heterozygous or homozygous HCLS1 Pro-Glu-Pro-Glu 366-367ins was significantly higher compared to that of healthy individuals (odds ratios 2.31 and 1.64, respectively; P = 0.0001389). The allele frequency of HCLS1 GluPro-Glu-Pro366-367ins was also significantly higher in patients with AML as compared with healthy individuals (35.2% versus 21.5%, odds ratio 1.7; P = 0.0005313). Notably, the high frequency of this insertion was previously described in patients with systemic lupus erythematosus and HCLS1 containing the inserted amino acids was shown to enhance B cell receptor signaling in B lymphocytes, inducing receptorindependent activation 48 . Similar mechanisms of HCLS1 hyperactivation could be applicable to AML blasts.
DISCUSSION
We identified HCLS1 to be crucial in at least three G-CSFR signaling pathways, connecting G-CSFR signaling with LEF-1 and with the PI3K-Akt and F-actin pathways (Fig. 6e) . Notably, interaction of HCLS1 with LEF-1 is essential for myeloid differentiation. The tyrosine kinases Lyn and Syk are essential for G-CSFR signaling in myeloid cells 15, 16, 23, 24 , and HCLS1 is a major substrate of Lyn and Syk 3,5-7 . We found that in myeloid cells Syk is constitutively associated with HCLS1, and upon G-CSF stimulation HCLS1 is tyrosine-phosphorylated and complexed with Lyn. The functional importance of HCLS1 for G-CSF-induced granulopoiesis is supported by the observation that G-CSF-triggered myeloid differentiation of CD34 + cells is substantially impaired after knockdown of HCLS1 or its binding partner HAX1. Patients with congenital neutropenia, who have disrupted G-CSFR-triggered granulopoiesis, have mutations in HAX1, leading to a lack of HAX1 protein 29 .
In these patients, G-CSF did not activate HCLS1 and LEF-1. Similarly, Hcls1 −/− mice have mild neutropenia and lower expression of LEF-1 in myeloid cells compared with WT mice. Because HAX1 is a ubiquitously expressed protein [30] [31] [32] [33] , it has been unclear why patients with congenital neutropenia have isolated neutropenia only. We found that in such patients with HAX1 mutations, G-CSF did not induce expression and function of the hematopoietic-specific HAX1-binding partner HCLS1. Therefore, we suggest that both HAX1 and HCLS1 are required for G-CSFR signaling and that downregulation of HCLS1 expression and functions causes isolated myeloid defects in patients with congenital neutropenia.
What is the mechanism of maturation arrest of granulopoiesis in patients with congenital neutropenia? We previously showed that LEF-1 is essential for granulocytic differentiation via binding to C/EBPα and that a lack of both LEF-1 and C/EBPα in myeloid progenitors from patients with congenital neutropenia caused maturation arrest of granulopoiesis 34 . However, the mechanisms by which LEF-1 is activated upon G-CSF stimulation and by which LEF-1 is downregulated in patients with congenital neutropenia downstream of HAX1 mutations have been unclear. In the search for a hematopoietic-specific binding partner of LEF-1, we found an interaction between the HCLS1 and LEF-1 proteins. This interaction is indispensable for G-CSF-dependent proliferation and differentiation of myeloid cells.
After tyrosine phosphorylation, HCLS1 translocates to the nucleus via its NLS 2 . B cell receptor (BCR) cross-linking causes nuclear translocation of tyrosine-phosphorylated HCLS1 that is mediated by Lyn and Syk 7 . We found that in CD34 + cells, HCLS1 interacts with LEF-1 and upon G-CSF stimulation is phosphorylated and translocates together with LEF-1 into the nucleus. Moreover, LEF-1 with a mutated HCLS1-binding site could not migrate to the nucleus, and LEF-1 was not found in the nucleus in the presence of HCLS1 lacking its NLS. This HCLS1 mutant did not activate the LEF1 gene promoter or induce LEF-1 mRNA expression, did not promote CFU-G colony formation and did not rescue defective granulopoiesis in Hcls1 −/− bone marrow cells in vitro, similarly to an HCLS1 mutant lacking the Y397 phosphorylation site. LEF-1 also has an NLS, and it has been assumed that LEF-1 translocates into the nucleus via the classical npg nuclear import pathway through binding of the LEF-1 NLS to importins (refs. 49,50) . However, recent studies have shown that the nuclear transport of LEF-1 is mediated by at least two independent pathways, one that depends on the NLS of LEF-1 and another that depends on LEF-1-binding partners. For example, β-catenin-dependent nuclear translocation of LEF-1 is independent of the LEF-1 NLS 51 . LEF-1 is a key protein in the Wnt signaling cascade, and the intracellular localization of LEF-1 varies depending on cell type and differentiation stage in order to regulate Wnt signaling appropriately. For example, in neurons and ectodermal cells LEF-1 is largely localized in the cytoplasm, whereas in astrocytes and mesodermal cells LEF-1 accumulates in the nucleus 52, 53 . In our study, we demonstrated the indispensable role of HCLS1 in nuclear transport of LEF-1 in CD34 + cells upon G-CSF-triggered myeloid differentiation, which is independent of the LEF-1 NLS. This nuclear transport also seems to be independent of β-catenin, given the similar behavior of dnLEF-1, which does not bind to β-catenin. Similarly to aspects of our model, LEF-1 directs the differentiation of keratinocyte stem cells along the hair follicle lineage via an interaction with the vitamin D receptor that is independent of β-catenin 54 . HCLS1 has not been reported to bind DNA or to be present on chromatin, and we did not detect HCLS1 associated with LEF-1 on chromatin of LEF-1 target genes. These results therefore indicate that HCLS1 is involved in the transport of LEF-1 into the nucleus but not in LEF-1 binding and activation of its target genes.
In addition to activating HCLS1 by phosphorylation, G-CSF induced mRNA and protein expression of HCLS1. The HCLS1 gene promoter has binding sites for the myeloid-specific transcription factors LEF-1 and C/EBPα, and LEF-1 activated HCLS1 expression by direct binding to the HCLS1 gene promoter. These data indicate the existence of a feedback loop by which G-CSF and LEF-1 promote HCLS1 expression, which in turn promotes LEF-1 function.
HAX1 is constitutively associated with HCLS1 30 , and we found that HAX1 is present in a complex with HCLS1 and LEF-1 and is essential for the HCLS1-LEF-1 interaction. These results may help explain how HAX1 mutations lead to isolated neutropenia in patients with congenital neutropenia.
An absence of HAX1 or HCLS1 in CD34 + cells led to abrogation of G-CSF-triggered activation of PI3K and Akt. Similarly, CD34 + cells from patients with congenital neutropenia with HAX1 mutations showed only marginal G-CSF-triggered activation of these proteins. Expression of HCLS1 lacking its NLS could not induce granulocytic differentiation or activate LEF-1 and had no effects on PI3K-Akt signaling. We therefore propose that both the Wnt-LEF-1 and PI3K-Akt pathways are involved in hematopoietic cell proliferation and granulocytic differentiation and that they act independently of each other. Microarray analysis of CD34 + cells deficient in HCLS1 protein showed downregulation of components of multiple signaling systems other than Wnt and PI3K-Akt. For instance, MDM2 was among the most downregulated genes, which regulates cell fate decision via its interaction with Numb 55 . HCLS1 has broad effects on hematopoietic cell proliferation and differentiation, and further functional studies are required.
HCLS1 is essential for G-CSFR-dependent F-actin rearrangement. HCLS1 contains F-actin-binding domains, which interact with actin filaments and regulate their assembly 3, 9, 11, 12 . In T and B lymphocytes, actin dynamics are controlled by tyrosine-phosphorylated HCLS1 in a complex with WASP and Arp2-Arp3. We previously showed that basal F-actin content in myeloid cells of patients with congenital neutropenia is greater than in cells of normal individuals, but that the increase in F-actin expression after G-CSF treatment is significantly lower compared to normal cells 47 . Consistent with those results, knockdown of HCLS1 or HAX1 in CD34 + cells of healthy individuals led to an increase in F-actin expression, which was not further elevated by G-CSF. Disturbed F-actin reorganization may lead to defective polarization and/or migration of hematopoietic cells within the bone marrow niche, which is essential for their differentiation 56 . F-actin might also function as a scaffold protein in G-CSFR signaling (for example, by acting as a scaffold for LEF-1).
HCLS1 may be involved in AML pathogenesis, as HCLS1 protein expression was substantially elevated in blasts of patients with AML as compared to bone marrow cells from healthy individuals. AML blasts respond hyperactively to hematopoietic cytokines such as G-CSF, GM-CSF, IL-3 and TPO, and also have greater levels of total protein tyrosine phosphorylation 57 . Autocrine production of hematopoietic cytokines such as GM-CSF, G-CSF, M-CSF and IL-6 by AML blasts has been reported [58] [59] [60] . In accordance with these data, we found extremely high autocrine production of G-CSF by AML blasts. High expression of G-CSF or other hematopoietic cytokines in AML blasts and the action of such cytokines in an autocrine or paracrine manner may induce hyperactivation of HCLS1 and lead to uncontrolled cell proliferation and reduced apoptosis. Indeed, in a meta-analysis of microarray data from patients with AML, we identified patients expressing high amounts of G-CSF, TPO or EPO or their receptors. The finding that hyperactivation of HCLS1 protein is involved in leukemic cell proliferation is also supported by data from patients with chronic lymphoblastic leukemia with poor prognosis; in these patients, HCLS1 is hyperphosphorylated owing to stimulation triggered by a persistent BCR-mediated Syk phosphorylation 13 . Moreover, we identified an insertion in the proline-rich region of HCLS1 in a majority of patients with AML. This insertion was previously identified in a mouse immature B lymphoma cell line in which it induced enhanced BCR-mediated signal transduction 48 . In AML, this insertion may lead to hyperactivation of cytokine signaling.
In summary, both HAX1 and HCLS1 are essential for multiple aspects of G-CSFR signaling pathways involving LEF-1, PI3K-Akt and F-actin and are essential for granulopoiesis. Our data suggest a dose-dependent function of HCLS1 in myeloid cell proliferation and differentiation: in congenital neutropenia HCLS1 is markedly downregulated and myelopoiesis is abrogated, whereas in AML HCLS1 is hyperactivated and associated with the high proliferative capacity of leukemic cells. We and others have described similar phenomena for LEF-1: in the absence of LEF-1, myeloid differentiation of human hematopoietic stem cells is markedly diminished 34 , and in a mouse model, constitutive hyperactivation of LEF-1 leads to hyperproliferative responses of hematopoietic cells with subsequent transformation into AML 41 .
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. Microarray data have been deposited in the Gene Expression Omnibus (GEO) database with accession code GSE40712.
(1:50 dilution, Cell Signaling, 45079) and mouse antibody to HAX1 (1:50 dilution, BD Bioscience, 610824). Cytospins were subsequently incubated with anti-mouse PLA-minus and anti-rabbit PLA-plus secondary probes for 45 min. Oligonucleotides complementary to the proximity probe DNA extensions were incubated in 1× hybridization solution for 15 min. To produce the rolling-circle amplification priming template, T4 DNA ligase (1:40) was added to samples, and samples were incubated for 15 min. Rolling-circle amplification of ligated oligonucleotide template was initiated by addition of Phi29 DNA polymerase followed by incubation for 90 min. Finally, Texas red-labeled oligonucleotide detection probes were incubated in 1× detection solution for 60 min. Cells were washed in PBS-T, in 2× SSC, in 0.2× SSC, in 0.02× SSC and in 70% ethanol. All washing procedures and washing solutions are described in the manufacturer's protocol. Samples were air dried and mounted with Olink mounting medium (Olink Bioscience) containing DAPI nuclear stain and examined with a Zeiss Axiovert Imager M1 epifluorescence microscope.
Coimmunoprecipitation. HEK293T cells were transfected with pcDNA-HCLS1 and pcDNA-LEF-1-HA-tag (LEF-1-HA-WT) or pcDNA-LEF-1-Ala16-HA-tag (LEF-1-HA-MUT) using Lipofectamine. 36 h after transfection, cells were lysed with RIPA buffer and LEF-1 protein was immunoprecipitated with protein G agarose beads conjugated with antibody to HA tag (Cell Signaling Technology). Endogenous LEF-1 protein from the Jurkat cell line was immunoprecipitated with protein G agarose beads conjugated with rabbit polyclonal antibody to LEF-1 (R.G.); endogenous HCLS1 protein from primary bone marrow CD34 + cells was immunoprecipitated with protein G agarose beads conjugated with rabbit polyclonal antibody to HCLS1 (Cell Signaling Technology) with subsequent washing out of proteins which nonspecifically bound to beads or antibody used for IP. Coimmunoprecipitates of either LEF-1 (with HCLS1 or with HAX1) or HCLS1 (with Lyn and Syk) proteins were eluted from the beads in Laemmli buffer and were detected by western blotting with the respective antibodies as indicated in the methods above for western blotting.
Colony-forming units assay. Human CD34 + cells were transduced with lentiviral constructs, as indicated in each experiment; GFP + or RFP + cells were sorted and plated in 1 ml methylcellulose medium (5 × 10 3 /dish; Methocult H4230; StemCell Technologies) supplemented with 10 ng/ml G-CSF or with cytokine cocktail (10 ng/ml of G-CSF, 10 ng/ml of GM-CSF, 10 ng/ml IL-3, 10 ng/ml of SCF and 1 U of EPO) (R&D Systems). After 14 d of culture, the numbers of CFU-G, CFU-GM and BFU-E colonies were calculated. Mouse bone marrow mononuclear cells were isolated by flushing the long bones with ice-cold PBS. Cells were plated in 1 ml methylcellulose medium (1 × 10 5 per dish; Methocult M3234; StemCell Technologies) supplemented with 10 ng/ml G-CSF or in methylcellulose medium with cytokine cocktail (Methocult GF M3434; StemCell Technologies). After 14 d of culture, the numbers of CFU-G, CFU-GM and BFU-E colonies were counted.
Cell stimulation, intracellular staining of proteins and analysis by FACS.
Serum-starved 293T-GCSFR, CD34 + or CD33 + cells were incubated with 10 ng/ml of rhG-CSF, washed in ice-cold PBS, fixed in 4% paraformaldehyde for 10 min, permeabilized with 0.5% Triton X-100 for 10 min and incubated with phalloidin-APC (F-actin staining, Invitrogen), rabbit polyclonal antibody to HCLS1 (4503S, 1:500), rabbit polyclonal antibody to phospho-HCLS1 (Tyr397, 4507S, 1:500), rabbit polyclonal antibody to Akt (9272, 1:500), rabbit polyclonal antibody to phospho-Akt (Ser473, 1:500, 9271), rabbit polyclonal antibody to PI3K p85 (4292, 1:500) (all from Cell Signaling Technology) or rabbit polyclonal antibody to phospho-PI3K p85 (Tyr467/Tyr199; Abcam, 1:500, ab63566) for 1 h at 4 °C. Cells were subsequently washed and stained with secondary FITC-or TRITC-conjugated antibody (Molecular Probes) and assessed by a FACSCalibur instrument.
In vitro cell proliferation. AML blasts were isolated from the peripheral blood or bone marrow of patients with AML using Ficoll density centrifugation. We cultured 1 × 10 5 of transduced and sorted RFP + AML blasts in RPMI 1640 medium supplemented with 10% FCS, 20 ng/ml interleukin-3 (IL-3), 20 ng/ml interleukin-6 (IL-6), 20 ng/ml thrombopoietin (TPO), 50 ng/ml stem cell factor (SCF) and 50 ng/ml Flt3-l (all purchased from R&D Systems). For assessment of proliferation, we counted viable cells using Trypan blue dye exclusion using a hemocytometer and determined cell proliferation using a luminescence-based cell proliferation kit from Promega. We determined the percentage of apoptotic cells using annexin V-FITC conjugate (Pharmingen).
LEF-1 cDNA synthesis and construction of LEF-1 cDNA and LEF-1 Ala16 cDNA containing lentiviral vectors. We amplified 1220-bp LEF-1 cDNA and cloned it into the pRRL.PPT.SF.i2GFPpre vector. This vector is a derivative of the standard lentiviral vector pRRL.PPT.PGK.GFPpre (provided by L. Naldini) 1 . Details are available upon request. To construct LEF-1 with a mutated HCLS1 binding site (LEF-1 Ala16), we replaced residues 186-192 in pRRL.PPT.SF.LEF-1.i2GFPpre with an alanine-glycine sequence using a site-directed mutagenesis kit from Invitrogen.
Promoter constructs and luciferase assays for LEF1, HCLS1, CEBPA and CCND1 gene promoter activity. We cloned human genomic DNA encompassing upstream regions of LEF1 (3,600 bp) or HCLS1 (1,600 bp) into a promoter-less luciferase construct, pGL4 Basic (Promega). The CEBPA promoter (5,400 bp) in the pGL3 vector was a gift from Q. Tong and the CCND1 promoter (1,748 bp) was a gift from O. Tetsu. We introduced point mutations into LEF-1-binding sites of LEF1, HCLS1 and CEBPA promoter constructs using the QuikChange II XL site-directed mutagenesis kit from Stratagene. Reporter plasmids along with pCMV-Renilla and expression plasmids containing cDNA or shRNA, as indicated in each experiment, were transfected into HEK293T cells using Lipofectamine or into CD34 + cells using Gene Pulser MXcell electroporation system and transfection reagent (Bio-Rad) according to the manufacturer's instructions. Transfected CD34 + cells were incubated with or without 10 ng/ml of rhG-CSF. After 36 h (for HEK293T cells) or 12 h (for CD34 + cells), cells were lysed and assayed with the Dual Luciferase Kit (Promega) according to the manufacturer's instructions. Luminescence was recorded by a Modulo 96 luminometer (Turner BioSystems).
Chromatin immunoprecipitation assays.
We cross-linked CD34 + cells (1 × 10 6 ) in 3.7% formaldehyde for 10 min at room temperature, stopped the cross-linking reaction by adding 0.125 M glycine, rinsed twice in icecold PBS with protease inhibitors (Halt protease inhibitor cocktail (100×), Pierce Thermo Scientific, 78429), resuspended in 1 ml of SDS lysis buffer containing protease inhibitors, and incubated for 10 min on ice. We sonicated DNA-protein complexes with three 15-s pulses at 50% of the maximum output using the HD 2070 sonicator from Bandelin Electronic. We set aside one-tenth of the sample for measurement of the input control, precleaned the remaining sample with blocked Staph A cells (Calbiochem, 507858), immunoprecipitated precleaned chromatin using the LEF-1-specific polyclonal antibody and eluted immunoprecipitated protein-DNA complexes. We reversed the cross-links with 0.3 M NaCl at 67 °C for 4 h and deproteinated samples with 20 mg/ml of proteinase K in the presence of 0.5% SDS. We detected LEF-1-associated DNA by PCR amplification using 200 ng of immunoprecipitated DNA or 200 ng of total input, followed by DNA sequencing using the dye terminator method (ABI).
Immunofluorescence staining and confocal microscopy. We stimulated 1 × 10 4 293T-G-CSFR cells with 10 ng/ml of rhG-CSF for 5 min, subsequently fixed them in 4% paraformaldehyde for 10 min, permeabilized with 0.5% Triton X-100 for 5 min, incubated with antibody to phalloidin (Invitrogen) for 1 h at 4 °C and assessed staining by confocal microscopy.
Mice. Male Hcls1 −/− mice on the C57BL/6J background have been described 16 . Male WT C57BL/6J mice were obtained from The Jackson Laboratory. All mice were housed under pathogen-free conditions in the Children's Hospital of Philadelphia animal facility. All studies involving animals were reviewed and approved by the Children's Hospital of Philadelphia Institutional Animal Care and Use Committee.
In vitro granulocytic differentiation of mouse bone marrow cells. Mouse bone marrow mononuclear cells were isolated by flushing the long bones with ice-cold PBS. Cells were plated in 1 ml Stemline II hematopoietic stem cell expansion npg medium (Sigma) supplemented with 10% FCS and cytokine cocktail (4 ng/ml mIL-3, 10 ng/ml hIL-6, 20 ng/ml hFlt-3L, 40 ng/ml IGF-1, 100 ng/ml mSCF and 1 mM dexamethasone). After 2 d of culture, cells were transduced with lentiviral constructs. After 3 d, transduced cells were placed in differentiation medium (RPMI supplemented with 10% FCS and cytokine cocktail (10 ng/ml hG-CSF, 10 ng/ml mGM-CSF, 5 ng/ml mIL-3, 10 ng/ml hIL-6, R& D Systems) for 7 d and with 10 ng/ml of G-CSF for four more days. The percentage of GFP + Gr-1 hi CD11b hi mature granulocytes was assessed by FACS.
Lentiviral transduction of CD34 + cells, primary blasts from patients with AML and cell lines. We used HEK293T cells for lentiviral supernatant production. HEK293T cells were maintained in DMEM supplemented with 10% FCS, 100 U/ml penicillin-streptomycin, and 2 mM glutamine. On the day before transfection, 5 × 10 6 HEK293T cells were plated on a 10-cm dish. For transfection, the medium was changed and 25 µM chloroquine (SigmaAldrich, Munich, Germany) was added. Transfer vector DNA (8 µg) and 5 µg of VSVg (glycoprotein of the vesicular stomatitis virus) envelope plasmid (A. Schambach) were used. In addition, 12 µg of a lentiviral Gag/Pol plasmid (pcDNA3 g/p 4xCTE) and 5 µg of a Rev plasmid (pRSV-Rev, provided by Thomas J. Hope) were co-transfected using the calcium phosphate technique. Medium was changed after 10-12 h. Transfection efficiency was monitored by FACS analysis. Supernatants containing the viral particles were collected 24-72 h after transfection, filtered through a 0.22-µm filter, concentrated by ultracentrifugation and stored at −80 °C until use. The virus titers averaged and were typically 1-5 × 10 8 IU/ml after ultracentrifugation. We transduced CD34 + cells from three healthy donors, primary blasts from three patients with AML and the NB4 cell line (2 × 10 5 per well) with lentiviral supernatants with a multiplicity of infection of 1-2, retransduced after 24 h and assessed transduction efficiency after 72 h as the percentage of RFP-positive cells.
Sequences of shRNAs.
The sequences of the shRNAs are as follows: anti-LEF-1a shRNA: 5'-GATCTTCGCCGAGATCAG-3'; anti-LEF-1b shRNA: 5'-CGACACTTCCATGTCCAG-3'; anti-HCLS1b shRNA: 5'-GACTACAA GGGAGAGACGGAG-3'; anti-HCLS1f shRNA: 5'-GAACCAGAGGGGGACT ATG-3'; anti-HAX1a shRNA 282: 5'-AATAGCATCTTCAGCGATA-3'; antiHAX1b shRNA 720: 5'-CGGACAGAGACTACAGTAA-3' .
Sequencing of the HCLS1 gene. We isolated DNA from blasts or mononuclear cells from peripheral blood from AML patients or healthy individuals, respectively, using the DNA Isolation Kit from Qiagen. We made primers for amplification of 12 exons with exon-intron boundaries of the HCLS1 gene, optimized PCR and sequencing conditions for each primer pair, amplified exons using PCR, purified PCR products using a QIAquick PCR purification kit from Qiagen (28106) and directly sequenced with the ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction Kit on a 3500 Genetic Analyzer (Applied Biosystems). We analyzed the data using 4peaks software (Mekentosj B.V.) and Chromas software.
Statistical analysis.
We performed statistical analysis using the SPSS V. 9.0 statistical package (SPSS) and a two-sided unpaired Student's t-test for analysis of differences in mean values between groups.
Additional methods. Additional methodology is described in Supplementary Methods. npg
